MedPath

Arthroscopic Treatment Combined With PRP Injection for Refractory Elbow Epicondylitis

Not Applicable
Active, not recruiting
Conditions
PRP
Lateral Epicondylitis
Interventions
Drug: normal saline
Registration Number
NCT04556825
Lead Sponsor
Beijing Jishuitan Hospital
Brief Summary

This study is a prospective randomized controlled study of different arthroscopic treatments for refractory external humeral epicondylitis combined with platelet rich plasma (PRP) injection. The patients with intractable external humeral epicondylitis were randomly divided into groups before the operation. After the arthroscopic operation was completed, they were divided into a local PRP injection group and a control group (normal saline) to perform additional operations on the damaged tendons, each for up to half a year after the operation. In different time periods, the quantitative and qualitative indicators including pain, functional score, muscle strength, MRI performance, etc. were compared between groups at the same time period to evaluate the difference in the effect of arthroscopic treatment combined with PRP on the treatment of damaged tendons. Determine the effectiveness of PRP. At the same time, in the process of arthroscopic treatment, look for risk factors that affect the curative effect of intractable external humeral epicondylitis, as well as the causes and prevention of common complications.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Clinically diagnosed patients with refractory external humeral epicondylitis (preoperative MRI confirmed loss of ECRB integrity) patients who have received non-surgical treatment with poor efficacy
  • Young and middle-aged patients aged 20 to 60, who have not previously received local injection therapy
  • Voluntarily accept randomized controlled grouping, cooperate with treatment and follow up patients
  • No other comorbidities or medical diseases affect the surgical patients
  • Unilateral disease
Exclusion Criteria
  • Early patients who have not received standard non-surgical treatment
  • Patients who have received hormone injections or "small needle knife therapy" and other invasive procedures within three months before surgery, poor skin conditions, and local infections
  • Elderly people older than 60 years old and patients younger than 20 years old
  • Unable to accept randomization, insufficient follow-up time or lost to follow-up
  • Bilateral disease
  • Combined immune disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control groupnormal salineArthroscopic treatment with normal saline injection
Study groupPRPArthroscopic treatment with PRP injection
Primary Outcome Measures
NameTimeMethod
Mayo Elbow Performance Score3, 6 weeks and 3, 6, 12, 24 months postoperatively

A score used to evaluated the elbow function, higher scores mean a better outcome.

Secondary Outcome Measures
NameTimeMethod
visual analog scale (VAS)3, 6 weeks and 3, 6, 12, 24months postoperatively

A score used to evaluated the elbow function, higher scores mean a better

scoring system of Verhaar3, 6 weeks and 3, 6, 12, 24months postoperatively

A score used to evaluated the elbow function, higher scores mean a better outcome

Disability of the Arm, Shoulder, and Hand (DASH)3, 6 weeks and 3, 6, 12, 24months postoperatively

A score used to evaluated the elbow function, higher scores mean a worse outcome.

Patient-Rated Tennis Elbow Evaluation (PRTEE) scale3, 6 weeks and 3, 6, 12, 24months postoperatively

A score used to evaluated the elbow function, higher scores mean a worse outcome

Integrity of the tendon in MRI3, 6, 12, 24 months postoperatively

MRI was performed to identify the status of the tendon

Trial Locations

Locations (1)

Beijing Jishuitan hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath